Bereda G. Hyperthyroidism: Definition, causes, pathophysiology and management. J Biomed Biol Sci. 2022;1(2):1–11.

khudhair Hussein D, Al-Jowari SAK, Rahmah AM. Determination of the Level of IL-6 and Vaspin in Hyperthyroid Patients Treated with Carbimazole. Iraqi J Sci. 2022;1909–17.

Hussein SZ, Farhan AS. Ferritin level in thyroid diseases. In: 1st scientific conference of medical group colleges. 2013. p. 26–7.

Hussein SZ, Ali SJ. Evaluation of Serum Thyroid Hormones and Cortisol Level in Patients with Chronic Renal Failure. In: 1st scientific conference of medical group colleges. 2013. p. 26–7.

Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update. Endocr Connect. 2013;2(4):R30–8.

Rafaqat S, Vujacic IR, Patoulias D, Khurshid H, Klisic A. Adipokines and Their Role in Acute Pancreatitis. J Med Biochem. 2024;43(4):512–27.

Gürel A, Doğantekin A, Özkan Y, Aydın S. Serum apelin levels in patients with thyroid dysfunction. Int J Clin Exp Med. 2015;8(9):16394–8.

Chen Y, Wu X, Wu R, Sun X, Yang B, Wang Y, et al. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism. Sci Rep. 2016;6(1):26174.

Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007;56(10):2533–40.

Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. Jama. 2016;315(21):2284–91.

Shan B, Wu F. Hydrogel‐based growth factor delivery platforms: strategies and recent advances. Adv Mater. 2024;36(5):2210707.

Liu J, Xu Y, Hu Y, Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64(3):380–90.

Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58(1):250–9.

Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148(2):774–81.

Adams AC, Astapova I, Badman MK, Kurgansky KE, Flier JS, Hollenberg AN, et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARα-dependent manner. J Biol Chem. 2010;285(19):14078–82.

Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol cell Biol. 2016;17(10):611–25.

Dai TT, Wang B, Xiao ZY, You Y, Tian SW. Apelin-13 upregulates BDNF against chronic stress-induced depression-like phenotypes by ameliorating HPA axis and hippocampal glucocorticoid receptor dysfunctions. Neuroscience. 2018;390:151–9.

Yang N, Li T, Cheng J, Tuo Q, Shen J. Role of apelin/APJ system in hypothalamic-pituitary axis. Clin Chim Acta. 2019;499:149–53.

Hollenberg AN. The role of the thyrotropin-releasing hormone (TRH) neuron as a metabolic sensor. Thyroid. 2008;18(2):131–9.

Akhondali Z, Badavi M, Dianat M, Faraji F. Co-administration of Apelin and T4 protects inotropic and chronotropic changes occurring in hypothyroid rats. Arq Bras Cardiol. 2015;105:235–40.

Gueorguiev M, Góth MI, Korbonits M. Leptin and puberty: a review. Pituitary. 2001;4:79–86.

Motawi TMK, Mahdy SG, El-Sawalhi MM, Ali EN, El-Telbany RFA. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis. Can J Physiol Pharmacol. 2018;96(1):38–44.

Menendez C, Baldelli R, Camina JP, Escudero B, Peino R, Dieguez C, et al. TSH stimulates leptin secretion by a direct effect on adipocytes. J Endocrinol. 2003;176(1):7–12.

Aksoy DY, Cinar N, Harmanci A, Karakaya J, Yildiz BO, Usman A, et al. Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy. Med Sci Monit Int Med J Exp Clin Res. 2013;19:210.

Çinar N, Gülçelik NE, Aydín K, Akín Ş, Usman A, Gürlek A. Serum vaspin levels in hypothyroid patients. Eur J Endocrinol. 2011;165(4):563–9.

Jing Han Zhang T-ou, Xiao W-hua, Chang C-qing, Hua Ai. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J (Engl). 2012;125(5):874–81.

Xiao F, Lin M, Huang P, Zeng J, Zeng X, Zhang H, et al. Elevated serum fibroblast growth factor 21 levels in patients with hyperthyroidism. J Clin Endocrinol Metab. 2015;100(10):3800–5.

Bonde Y, Breuer O, Lütjohann D, Sjöberg S, Angelin B, Rudling M. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans [S]. J Lipid Res. 2014;55(11):2408–15.

Lee Y, Park YJ, Ahn HY, Lim JA, Park KU, Choi SH, et al. Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile. Endocr J. 2013;60(8):977–83.

Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab. 1998;83(11):3908–12.

Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene. 1997;15(22):2687–98.

Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–5.

Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82(5):864–73.

Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, et al. Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest. 1995;96(3):1295–302.

Suzuki K, Mori A, Saito J, Moriyama E, Ullianich L, Kohn LD. Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene. Endocrinology. 1999;140(11):5422–30.

Castagnone D, Rivolta R, Rescalli S, Baldini MI, Tozzi R, Cantalamessa L. Color Doppler sonography in Graves’ disease: value in assessing activity of disease and predicting outcome. AJR Am J Roentgenol. 1996;166(1):203–7.

Ferrara N, Houck K, Jakeman LYN, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.

Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery. 1996;120(6):944–7.

Sato K, Miyakawa M, Onoda N, Demura H, Yamashita T, Miura M, et al. Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab. 1997;82(6):1968–73.

Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 1995;11(8):1569–79.